NCT07050459

A Phase I Study of SIM0686 in Participants With Locally Advanced/Metastatic Solid Tumors

A Phase I First-in-Human, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0686 in Adult Participants With Locally Advanced/Metastatic Solid Tumors

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 220 (estimated)
• Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, multicenter phase 1 study to evaluate the safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0686 in Adult Participants with Locally Advanced/Metastatic Solid Tumors

Conditions

• Locally Advanced Solid Tumors

Interventions

Type	Name	Description
DRUG	SIM0686	Administered intravenously
DRUG	SIM0686	Administered intravenously

Timeline

• Start date: 2025-05-20
• Primary completion: 2027-12-01
• Completion: 2028-12-01
• First posted: 2025-07-03
• Last updated: 2025-07-03

Locations

10 sites across 1 country: China